NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$20.21
-5.12 (-20.21%)
Close of Nov 06, 2026 · end-of-day data
AORT 8-K filings in 2024
Every material Form 8-K Artivion filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Artivion reported third-quarter 2024 results on November 7, 2024. Revenue rose 9% to $95.8 million from $87.9 million a year earlier, and the GAAP net loss narrowed to $2.3 million, or $0.05 per diluted share, from $9.8 million, or $0.24 per share. The company narrowed its full-year 2024 revenue guidance to $389 million to $396 million, with the low end raised from $388 million, and kept its adjusted EBITDA outlook of $69 million to $72 million.
Q3 2024 revenue was $95.8 million, up 9% on a GAAP basis and 10% in constant currency, versus $87.9 million in Q3 2023.
GAAP net loss was $2.3 million ($0.05 per diluted share), compared with a $9.8 million loss ($0.24 per share) a year earlier; non-GAAP net income was $5.0 million ($0.12 per share).
Full-year 2024 revenue guidance narrowed to $389 million to $396 million, from $388 million to $396 million previously.
Adjusted EBITDA rose 28% to $17.7 million in Q3 2024; full-year adjusted EBITDA is still expected at $69 million to $72 million.
Artivion reported second-quarter 2024 revenue of $98.0 million, up 10% from $89.3 million a year earlier, and a net loss of $2.1 million ($0.05 per diluted share), narrower than the $3.4 million loss ($0.08 per share) in the prior-year quarter. The company raised its full-year 2024 revenue and adjusted EBITDA guidance, though the increases at the midpoint are small.
Q2 2024 revenue $98.0 million vs. $89.3 million in Q2 2023, up 10% on both GAAP and constant currency bases
Q2 2024 net loss of $2.1 million ($0.05 per diluted share) vs. net loss of $3.4 million ($0.08 per share) in Q2 2023; non-GAAP net income $2.9 million ($0.07 per share)
Adjusted EBITDA rose 35% to $18.6 million from $13.8 million
FY24 revenue guidance raised to $388 million to $396 million from $386 million to $396 million; adjusted EBITDA guidance raised to $69 million to $72 million from $68 million to $72 million
Artivion amended its 2019 loan and purchase option agreements with Endospan Ltd., a privately held developer of the NEXUS stent graft system. Artivion will provide up to $25 million in additional secured loans, and the option's upfront payment is cut from $250 million to $175 million, or $135 million after loan offset. The company does not expect the amended agreement to have a material impact on its full-year 2024 guidance, and the option takes effect only if Artivion exercises it.
Up to $25 million in new secured loans to Endospan, in tranches of $7 million, $10 million and $8 million; first tranche to be funded as soon as practicable
Loans bear 5% annual interest and are due on the earlier of a third-party acquisition of Endospan or December 31, 2027
Upfront purchase payment reduced from $250 million to $175 million, or $135 million inclusive of loan offset; $100 million minimum earnout eliminated
Company does not anticipate a material impact on full-year 2024 financial guidance
Artivion reported first-quarter 2024 revenue of $97.4 million, up 17% from $83.2 million a year earlier, and net income of $7.5 million, or $0.18 per diluted share, compared with a net loss of $13.5 million a year earlier. The company raised the low end of its full-year 2024 revenue guidance to $386 million to $396 million, while its adjusted EBITDA forecast of $68 million to $72 million was unchanged.
Q1 2024 revenue $97.4 million, up 17% on a GAAP basis and 16% in constant currency
Net income $7.5 million ($0.18 per diluted share) vs. net loss of $13.5 million ($0.33 per share) in Q1 2023; non-GAAP net income $2.6 million ($0.06 per share)
Non-GAAP adjusted EBITDA rose 60% to $17.3 million from $10.8 million
FY2024 revenue guidance $386 million to $396 million (previously $382 million to $396 million); adjusted EBITDA guidance $68 million to $72 million unchanged
Artivion reported fourth-quarter 2023 revenue of $93.7 million, up 18% on a GAAP basis from a year earlier, and full-year revenue of $354.0 million, up 13%. The company swung to a fourth-quarter net loss of $4.0 million, or $0.10 per diluted share, from net income of $2.2 million, or $0.05 per share, a year earlier. It also guided to 2024 revenue of $382 million to $396 million and non-GAAP adjusted EBITDA of $68 million to $72 million.
Q4 2023 revenue was $93.7 million, up 18% GAAP and 15% constant currency from $79.4 million in Q4 2022
Q4 2023 net loss was $4.0 million ($0.10 per diluted share) versus net income of $2.2 million ($0.05) in Q4 2022
Full-year 2023 net loss was $30.7 million ($0.75 per share); non-GAAP adjusted EBITDA rose to $53.8 million
2024 outlook: revenue of $382 million to $396 million (8% to 12% growth) and adjusted EBITDA of $68 million to $72 million
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Artivion filing is on SEC EDGAR ↗. 8-K briefs of other companies →